SG11202007966UA - Therapeutic uses of glp1r agonists - Google Patents
Therapeutic uses of glp1r agonistsInfo
- Publication number
- SG11202007966UA SG11202007966UA SG11202007966UA SG11202007966UA SG11202007966UA SG 11202007966U A SG11202007966U A SG 11202007966UA SG 11202007966U A SG11202007966U A SG 11202007966UA SG 11202007966U A SG11202007966U A SG 11202007966UA SG 11202007966U A SG11202007966U A SG 11202007966UA
- Authority
- SG
- Singapore
- Prior art keywords
- therapeutic uses
- glp1r agonists
- glp1r
- agonists
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668384P | 2018-05-08 | 2018-05-08 | |
| PCT/US2019/030110 WO2019217165A1 (en) | 2018-05-08 | 2019-05-01 | Therapeutic uses of glp1r agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007966UA true SG11202007966UA (en) | 2020-11-27 |
Family
ID=66484210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007966UA SG11202007966UA (en) | 2018-05-08 | 2019-05-01 | Therapeutic uses of glp1r agonists |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210023072A1 (https=) |
| EP (1) | EP3790549A1 (https=) |
| JP (2) | JP2021523877A (https=) |
| KR (2) | KR20260036616A (https=) |
| AU (2) | AU2019266114A1 (https=) |
| CA (1) | CA3090823A1 (https=) |
| MX (1) | MX2020008387A (https=) |
| SG (1) | SG11202007966UA (https=) |
| WO (1) | WO2019217165A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| US12459954B2 (en) | 2020-04-01 | 2025-11-04 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Crystalline form a of GLP-1 receptor agonist and preparation method therefor |
| JP2023528726A (ja) * | 2020-04-01 | 2023-07-06 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法 |
| CN115667222B (zh) * | 2020-05-28 | 2023-09-29 | 杭州中美华东制药有限公司 | 一种制备glp-1受体激动剂的方法 |
| EP4213847A4 (en) * | 2020-09-21 | 2024-12-04 | vTv Therapeutics LLC | AMORPHOUS FORM OF AN ISOQUINOLINE DERIVATIVE |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304712A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| KR102920994B1 (ko) | 2024-05-20 | 2026-02-02 | (주)인벤티지랩 | 오르포르글리포론 또는 이의 약학적으로 허용되는 염을 포함하는 마이크로 입자 및 이의 제조 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000042026A1 (en) * | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| CN102378574B (zh) | 2009-03-30 | 2013-11-20 | 转化技术制药公司 | 取代的偶氮蒽衍生物、药物组合物及其使用方法 |
| US20110064806A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
| EA201491749A1 (ru) * | 2012-03-22 | 2015-01-30 | ТРАНСТЕК ФАРМА, ЭлЭлСи | Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение |
| AU2014207748B2 (en) * | 2013-01-17 | 2018-10-11 | Vtv Therapeutics Llc | Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
-
2019
- 2019-05-01 MX MX2020008387A patent/MX2020008387A/es unknown
- 2019-05-01 WO PCT/US2019/030110 patent/WO2019217165A1/en not_active Ceased
- 2019-05-01 KR KR1020267006272A patent/KR20260036616A/ko active Pending
- 2019-05-01 CA CA3090823A patent/CA3090823A1/en active Pending
- 2019-05-01 JP JP2020544255A patent/JP2021523877A/ja active Pending
- 2019-05-01 KR KR1020207026027A patent/KR20210005843A/ko not_active Ceased
- 2019-05-01 AU AU2019266114A patent/AU2019266114A1/en not_active Abandoned
- 2019-05-01 SG SG11202007966UA patent/SG11202007966UA/en unknown
- 2019-05-01 EP EP19723616.9A patent/EP3790549A1/en active Pending
-
2020
- 2020-10-13 US US17/069,453 patent/US20210023072A1/en not_active Abandoned
-
2024
- 2024-05-17 JP JP2024081189A patent/JP2024112903A/ja active Pending
- 2024-11-07 US US18/940,597 patent/US20250325536A1/en active Pending
-
2025
- 2025-03-13 AU AU2025201814A patent/AU2025201814A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020008387A (es) | 2020-12-11 |
| CA3090823A1 (en) | 2019-11-14 |
| TW202015683A (zh) | 2020-05-01 |
| US20250325536A1 (en) | 2025-10-23 |
| EP3790549A1 (en) | 2021-03-17 |
| WO2019217165A1 (en) | 2019-11-14 |
| KR20210005843A (ko) | 2021-01-15 |
| JP2024112903A (ja) | 2024-08-21 |
| KR20260036616A (ko) | 2026-03-17 |
| AU2019266114A1 (en) | 2020-08-27 |
| AU2025201814A1 (en) | 2025-04-03 |
| JP2021523877A (ja) | 2021-09-09 |
| US20210023072A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202007966UA (en) | Therapeutic uses of glp1r agonists | |
| IL274723A (en) | Interleukin-2 partial agonists | |
| IL272888B1 (en) | Uses of piperidinyl-indole derivatives | |
| IL259040A (en) | Use of tlr8 agonists to treat cancer | |
| ZA201701644B (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| IL276592A (en) | History of Subtirum | |
| ZA201906238B (en) | New therapeutical use of h3-ligands | |
| PT3661491T (pt) | 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| LT3145530T (lt) | Trail receptoriaus agonistai, skirti fibrozinių ligų gydymui | |
| IL289338B1 (en) | Therapeutic interactions of leucomethylthioninium | |
| GB201709136D0 (en) | New therapeutic uses of enzyme inhibitors | |
| IL274747A (en) | FXR agonists for the treatment of liver diseases | |
| IT201700086482A1 (it) | Composizione per il trattamento della vaginosi batterica | |
| GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
| SG11202105136WA (en) | Application of chidamide | |
| HK40048605A (en) | Therapeutic uses of glp1r agonists | |
| EP3110799A4 (en) | Heterocyclic inhibitors of the sodium channel | |
| GB201809911D0 (en) | Use of trpv1 agonists | |
| GB201720445D0 (en) | Use of TRPV1 agonists | |
| GB201810835D0 (en) | Methods of use | |
| GB201620933D0 (en) | Use of TRPV1 agonists | |
| GB201618031D0 (en) | New therapeutic uses of enzyme inhibitors | |
| GB201721386D0 (en) | Chrondogy of time-wave | |
| IT201700108033A1 (it) | Composizione per il trattamento della costipazione |